Table 6.

Results of sputum samples from previously treated suspected MDR-PTB cases tested using Xpert MTBC/RIF and MGIT 960 System during 2016–2018.

Total sputum samples	Xpert MTB/RIF	MGIT 960
402	MTBC Pos (384/402, 95.52%)	MTBC Pos (336/402, 83.58%)
	RS	RR	RS	HS	SS	ES	AmkS	KmS	OflS
	2/384 (0.52%)	366/384 (95.31%)	41/336 (12.20%)	71/336 (21.13%)	269/336 (80.05%)	241/336 (71.72%)	336/336 (100%)	326/336 (97.02%)	302/336 (89.88)

RS: Rifampicin sensitive; RR: Rifampicin resistant; HS: Isoniazid sensitive; SS: Streptomycin sensitive; ES: Ethambutol sensitive; AmkS: Amikacin sensitive; KmS: Kanamycin sensitive OflS: Ofloxacin sensitive.